HBA120 Hepatitis B Vaccine Description
HBAI20 vaccine candidate consists of a standard HBV vaccine to which the AI20 adjuvant is added.
The adjuvant can give an additional stimulus to the immune system and provide sufficient protection against HBV for the non-responders.
CyTuVax has successfully finished Phase 1 clinical study of HBAI20, a specialized vaccine for people who were initially non-responders to standard hepatitis B vaccination. To read more about this study, see the publication of O. Koc et al. (2018). The phase 1 clinical trial showed that the HBAI20 vaccine was well tolerated among study participants and induced protective anti-hepatitis B-antibody titers in 9 out of 10 participants who were initially non-responders to standard hepatitis B vaccines.
CyTuVax is currently investigating, in a phase 2 clinical trial, the efficacy of the HBAI20 vaccine to induce seroprotection and compare the safety of the HBAI vaccine with the standard hepatitis B vaccination.
HBA120 Hepatitis B Vaccine Indication
The HBA120 vaccine candidate is indicated for HBV non-responders.
Also, the HBAI20 gives faster protection, offering fewer vaccinations in the future.
HBA120 Hepatitis B Vaccine Clinical Trials
Clinical Trial NCT03415672: Hepatitis B Vaccine for Non-responders. Last Update Posted: January 31, 2019.
In this Phase 2 trial, the investigators study the efficacy of the HBAI20 vaccine to induce seroprotection in registered non-responders (adults who were previously vaccinated with the HBVaxPro-10μg but did not achieve seroprotection). The study will further assess the safety of the HBAI20 vaccine in comparison with HBVaxPro-10μg.